US-based biotech igniter General Inception has announced the acquisition of Enable Medicine, which leverages AI for biological data analysis, for an undisclosed amount.
The two companies are also expanding their existing partnership, initiated last year to establish Ennovate Pharma, which focuses on autoimmune and inflammatory diseases.
The partnership aims to enhance their AI-powered drug discovery capabilities.
It widens General Inception’s access to Enable Medicine’s biological data platform that supports life science and biopharmaceutical researchers.
Also, the partnership allows Enable Medicine to benefit from General Inception’s drug development expertise and biotech ecosystem.
Enable Medicine co-founder and chief scientific officer Aaron Mayer said: “Generative biological search of our Atlas of disease is unlocking the next generation of drug discovery.
“By working with General Inception, and its global network of experienced executives and drug developers, we will be able to jointly accelerate target discovery, develop optimal patient treatment strategies, and improve clinical drug positioning.”
Enable Medicine harnesses AI capabilities to novel insights into biology and medicine.
Its AI platform unlocks the power of generative biological search, which uses cutting-edge AI models to search maps of disease for novel drug targets and indications.
The approach prioritises indexing high-quality multimodal cellular data to help the research and pharmaceutical industry experts working on complex diseases.
Enable Medicine scientific advisory board member James Zou said: “Enable Medicine has developed a hugely powerful new way of indexing and interrogating biological data to speed up this vital process.
“This partnership with General Inception will ensure its transformative technology can be put to use by many top researchers, working in a wide range of areas including cancer, autoimmune and inflammatory disease.”
Biological data is often complex, fragmented, inaccessible, and siloed, limiting critical insights and hindering therapeutic discovery.
Enable Medicine is developing a large-scale biological atlas to index, integrate, and evaluate multimodal datasets to generate disease-relevant insights and advance discovery.
Furthermore, General Inception and Enable Medicine are seeking partnerships with healthcare providers and data repositories to develop better drugs and treatment strategies.
Enable Medicine president and General Inception chief scientific officer Venkat Reddy said: “After the resounding success of our first collaboration, we have seen the tremendous power of Enable Medicine’s platform and approach.
“By investing in Enable Medicine, and gaining access to their unique data and analytics platform, we can build a powerful new drug discovery offering.”
